ReviewCurrent opinion in gastroenterology2013
Metabolomics: is it useful for inflammatory bowel diseases?
Review in Current opinion in gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease.Applied microbiology and biotechnology · 2019Trial
- Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission.PloS one · 2015Trial
- A longitudinal comparative analysis of serum metabolomic signatures in children with SARS-CoV-2 infection and MIS-C.Communications medicine · 2026Article
- Predicted meta-omics: A potential solution to multi-omics data scarcity in microbiome studies.PloS one · 2026Article
- Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.Inflammatory bowel diseases · 2024Article
- A comprehensive overview of microbiome data in the light of machine learning applications: categorization, accessibility, and future directions.Frontiers in microbiology · 2024Review
- Biological markers of disease activity in inflammatory bowel diseases.Przeglad gastroenterologiczny · 2023Review
- Mushroom polysaccharides fromFrontiers in pharmacology · 2023Article
- Serum metabolomic profiles in dogs with chronic enteropathy.Journal of veterinary internal medicine · 2022Article
- The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease.Gut pathogens · 2022Article
- Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets.Gastroenterology · 2022Article
- Systematic Review of Recent Lipidomics Approaches Toward Inflammatory Bowel Disease.Biomolecules & therapeutics · 2021Review
- Chronic Abdominal Pain in IBD Research Initiative: Unraveling Biological Mechanisms and Patient Heterogeneity to Personalize Treatment and Improve Clinical Outcomes.Crohn's & colitis 360 · 2021Article
- PepT1-knockout mice harbor a protective metabolome beneficial for intestinal wound healing.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Metabolomics facilitate the personalized management in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2021Review
- A literature-based approach for curating gene signatures in multifaceted diseases.Journal of translational medicine · 2020Article
- Article
- Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.Journal of translational medicine · 2019Review
- Korean Traditional Medicine (Metabolites · 2019Article
- Chronic refined low-fat diet consumption reduces cholecystokinin satiation in rats.European journal of nutrition · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
purpose of reviewThe assessment of metabolite profiles in biofluids has become a powerful method for the detection of biomarker molecules and disease mechanisms. This review outlines the recent advances in the use of metabolomic techniques to study inflammatory bowel diseases (IBDs). RECENT
findingsThe last few years have seen an increase in the studies of experimental and human IBD focusing on the search for small metabolites, such as amino acids, bases, and tricarboxylic acid cycle intermediates. Experimental methods for the screening of metabolites in serum, urine, fecal extracts, and colon tissue include H NMR spectroscopy, gas chromatography-mass spectrometry, and liquid chromatography methods. Several studies demonstrate that IBD patients and healthy individuals, as well as the IBD subtypes, can be distinguished using metabolic profiling. Metabolomic data of fecal extracts and urine have revealed disruptions in bacterial populations, findings that are indicative of a possible involvement of the microbiome in the development of IBDs. SUMMARY: Metabolites from biofluids can be detected in IBDs by different experimental methods that allow successful separation of IBD subtypes from healthy cohorts. Knowledge of a unique metabolomic fingerprint in IBDs could be useful for diagnosis, treatment, and detection of disease mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.